<DOC>
	<DOCNO>NCT01092104</DOCNO>
	<brief_summary>A double-blind , randomize , placebo-controlled , dose-escalating study assess antiviral activity , safety , tolerability , pharmacokinetics ( PK ) CCR5 antagonist TBR 652 monotherapy dose orally daily ( QD ) 10 day HIV 1-infected , antiretroviral treatment-experienced , CCR5 antagonist-naïve patient .</brief_summary>
	<brief_title>A Proof Concept Study Evaluate Antiviral Activity , Safety , Pharmacokinetics CCR5 Antagonist TBR 652 HIV 1-Infected , Antiretroviral Treatment-Experienced , CCR5 Antagonist-Naïve Patients</brief_title>
	<detailed_description />
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>TAK-652</mesh_term>
	<criteria>1 . No clinically significant finding Screening evaluation ( clinical , laboratory , ECG ) , opinion Investigator would interfere subject 's ability comply protocol . 2 . Antiretroviral treatmentexperienced ; antiretroviral therapy least 6 week prior study entry . 3 . CCR5 antagonist therapy naive . 4 . CD4 cell count &gt; /= 250 cells/mm3 Screening ( within 30 day prior first dose ) . 5 . Two separate qualify plasma HIV 1 RNA level &gt; /= 5,000 copies/mL within 45 day prior first dose . 6 . Females reproductive potential ( document surgically sterile postmenopausal [ define amenorrhea ≥ 1 year follicle stimulate hormone { FSH } ≥ 30 mU/mL ] ) . 7 . Females childbearing potential may enrol follow negative serum pregnancy test . If participating activity could lead pregnancy , male females shall agree use two form barrier method contraception trial 2 month stop medication . 1 . Presence CXCR4 dual/mixedtropic HIV 1 virus . 2 . Active CDC category C disease ( except cutaneous Kaposi 's sarcoma require systemic therapy trial ) . 3 . History infection hepatitis B hepatitis C virus , history cirrhosis , know active chronic liver disease . NOTE : Hepatitis B vaccinate patient eligible . 4 . Serum ALT AST value great Grade 1 bilirubin value great upper limit normal ( ULN ) Screening . 5 . History HIV2 . 6 . Recent history ( &lt; 30 day prior study drug administration ) clinically significant infection . 7 . Pregnant female female breastfeed . 8 . Treatment immunomodulating agent ( systemic corticosteroid , interleukin , interferon ) agent know antiHIV activity within 30 day prior study drug administration . 9 . Treatment vaccine within 30 day study drug administration . 10 . A positive prestudy drug screen , include amphetamine , barbiturate , cocaine , PCP . 11 . Anticipated use antacid trial and/or within 7 day prior first dose study drug . 12 . Current alcohol drug use , expert judgment investigator , interfere patient 's ability comply protocol requirement . 13 . Inability , opinion investigator , comply dose schedule protocol evaluation . 14 . Use experimental medication within 4 week prior Screening . 15 . Current ( within 30 day prior first dose study drug ) anticipate use antimetabolites ; alkylating agent ; drug , herbal preparation , food ( include grapefruit ) know affect CYP 3A4 CYP 2C8 enzyme Pglycoprotein transporter . 16 . History clinically significant hepatic , metabolic , endocrine , renal , hematologic , pulmonary , gastrointestinal , cardiovascular disorder ( include ECG abnormality ) . 17 . Uncontrolled hypertension . 18 . Presence malabsorption syndrome affect drug absorption ( e.g. , Crohn 's disease , chronic pancreatitis ) . 19 . History malignancy exception cure basal squamous cell carcinoma skin . 20 . Receipt radiation cytotoxic chemotherapeutic agent recover side effect prior first dose study medication . 21 . Subjects use overthecounter medication ( include phytotherapeutic , herbal , plantderived preparation ) within 14 day prior first dose study medication , unless approve Investigator , use St. John 's wort within 21 day prior first dose study drug . ( St. John 's wort prohibit study . ) 22 . History presence abnormal ECG .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>